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ABSTRACT
Parkinson’s disease (PD) is a neurodegenerative disease that is characterized by motor and non-motor symptoms which 
result from the progressive degeneration of nigrostriatal ventral midbrain (VM) dopaminergic (DA) neurons, as well as 
peripheral sympathetic neurons. PD is incurable, with current therapeutic strategies providing symptomatic relief. Neu-
rotrophic factor (NTF) therapy has the potential to protect degenerating neurons in PD. However, there has been limited 
success in PD clinical trials due to neurotrophic strategies that are invasive, inefficient in delivering sustained neurotrophic 
support, do not protect all degenerating neurons and may have a compromised mechanism of action in the PD brain. 
Therefore, while neurotrophic therapy remains a promising disease-modifying approach for PD, it is important to identify 
novel neurotrophic strategies that can protect all neurons affected by PD. To address this need, we report an integrated 
approach for pre-clinical evaluation of potential neurotrophic strategies, e.g., pharmacological agents (e.g., drugs/small 
molecules), signaling proteins (e.g., morphogens) and/or genetic (gene/mRNA) modifications, in cellular models of the 
neuronal populations that are affected by PD. Herein, we describe, in detail, an in vitro protocol that allows a step-wise 
evaluation of the efficacy, and mechanism(s) of action, of novel neurotrophic strategies in VM DA neurons and sympathetic 
neurons, following an initial evaluation in a human cell line model of these cells, SH-SY5Y cells. The protocol uses the 
induction of neurite growth as the primary measure of neurotrophic action. Indeed, the neuro-protection/-restoration of 
PD-affected axons is widely thought to be an appropriate target for effective therapeutic intervention in PD.
Keywords: neurite growth analysis, dopaminergic neuron, Parkinson’s disease, neurotrophic therapy, sympathetic neuron
BACKGROUND
Parkinson’s disease (PD) is the second most common neurodegen-
erative disease that affects 1–2% of people over the age of 65, and this 
incidence significantly increases with age [1]. In PD, the progressive 
degeneration of ventral midbrain (VM) dopaminergic (DA) neurons 
of the nigrostriatal pathway results in reduced DA neurotransmis-
sion in the striatum, leading to motor dysfunction. PD is thus largely 
characterized as a motor disorder, but also presents with a variety of 
accompanying non-motor symptoms [2,3]. Another defining feature 
of PD is the pathological accumulation of intraneuronal Lewy bodies, 
consisting predominantly of α-synuclein, that are found throughout the 
central, peripheral, and autonomic nervous systems [4-6]. In parallel to 
the striatal DA denervation [7], there is also heterogeneous peripheral 
denervation [8-10], such as sympathetic denervation of the left ven-
tricular myocardium that leads to hypotension [11]. Despite decades of 
research, current PD treatments are symptomatic and mainly involve 
dopamine-replacement strategies. However, these treatments wear 
off over time and do not slow, prevent or reverse the degeneration of 
neurons affected by PD [12].
At present, neurotrophic factor (NTF) therapy is one of the most 
promising disease-modifying therapies for PD. NTFs are critical for 
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the survival and growth of neurons in the nervous system. A number 
of neurotrophic factors have been shown to promote the survival and 
growth of VM DA neurons in vitro and in vivo, many of which are 
members of the transforming growth factor β superfamily including 
glial cell line-derived neurotrophic factor (GDNF), neurturin (NTN) and 
growth/differentiation factor 5 (GDF5) [13-15]. The application of NTFs 
to the striatum and/or VM thus has the potential to protect degenerating 
VM DA neurons in PD [14]. However, this approach has had limited 
success in clinical trials to date [14-16]. One potential explanation for 
ineffectiveness of GDNF and NTN NTFs, used in these clinical trials, is 
the suggestion that these NTFs may not be capable of signaling in the PD 
brain. Indeed, α-synuclein has been shown to downregulate expression 
of the GDNF/NTN receptor, RET, in the α-synuclein rat model of PD, 
in which GDNF has no neurotrophic effects [17,18]. Indeed, authors 
of the most recent NTF PD clinical trial suggested that “better results 
might be achieved with other trophic factors that are not RET dependent” 
[16]. In addition to this, localised administration of NTF ligands in PD 
will not protect the other peripheral/autonomic neurons affected by PD. 
Furthermore, such intracerebral administration is invasive, and inefficient 
in its delivery of sustained neurotrophic support [15]. Therefore, while 
neurotrophic therapy remains a promising disease-modifying approach 
for PD, it is important to identify novel neurotrophic strategies that may 
be useful in protecting all neurons affected by PD.
In order to develop novel neurotrophic strategies, we need a systematic 
protocol for pre-clinical evaluation of potential neurotrophic strategies 
in neuronal populations which are affected by PD. The mechanisms 
of action of any neurotrophic strategies also needs to be characterized 
in order to ensure that such mechanisms are capable of functioning in 
the PD brain before trials in humans. Herein we report an integrated 
approach for investigating neurotrophic efficacy in VM DA and sympa-
thetic neurons, following initial evaluation in a human cell line model 
of these neuronal populations that are affected by PD. As neurotrophic 
factors function to promote the survival and neurite growth of neurons 
during development and in adulthood, this protocol focuses on the 
induction of neurite growth as the primary measure of neurotrophic 
action. Indeed, neuro-protection/-restoration of PD-affected neurites is 
essential to modify the progression of PD, as axonal degeneration has 
been reported to be the earliest pathological feature of PD, as well as an 
appropriate promising target for effective therapeutic intervention [19].
MATERIALS
Animals
Embryonic day (E) 14 embryos were removed by laparotomy from 
euthanized time-mated Sprague-Dawley rats. Postnatal day (P) 1 C57 
mice or Sprague-Dawley rats were decapitated. All animals were provided 
by Biological Services Unit, University College Cork, and procedures 
were carried out with approval of the Animal Experimental Ethics 
Committee of University College Cork.
Equipment
 9 Class II Microflow Biological Safety Cabinet
 9 Tissue Culture Incubator (ThermoForma Series II, Thermo 
Electron Corporation)
 9 15 ml conical centrifuge tubes (Corning)
 9 0.5/1.5 ml Eppendorfs (Greiner)
 9 T25 flasks (Greiner)
 9 24-well and 6-well plate tissue culture plates (Sarstedt)
 9 Plugged and unplugged flame-polished glass Pasteur pipettes 
(Sarstedt)
 9 Haemocytometer (Marenfield Superior)
 9 90 mm Petri dish (Fannin Healthcare)
 9 Dissection microscope (Leica Wild M8) in a fume hood 
(Brassaire)
 9 Dissecting scissors, tweezers and a curved forceps (World 
Precision Instruments)
 9 5 ml syringe (BD PlastipakTM) and 1.10 × 30 mm needle 
(Sterican)
 9 4 well 35 mm tissue culture dishes (Greiner)
 9 Centrifuge (15 ml tubes & eppendorfs)
 9 NeonTM Transfection System electroporator, pipette, cuvette 
and tips (Invitrogen)
 9 Microplate spectrophotometer and laboratory rocker
 9 Olympus IX70 inverted microscope fitted with Olympus DP70 
camera (Mason Technology)
 9 Scaled 1 mm micrometer slide (GT Vision)
 9 AnalysisD, ImageJ, GraphPad Prism and Matlab software
Reagents
 9 Human SH-SY5Y Neuroblastoma Cell Line (Sigma, cat. # 
94030304)
 9 Foetal bovine serum (FBS; Sigma, cat. # F2442)
 9 Trypsin (Sigma, cat. # T6567)
 9 Dimethyl Sulfoxide (DMSO; Sigma, cat. # D2650)
 9 Dulbecco’s Modified Eagle Medium Nutrient Mixture F-12 
(DMEM-F12; Sigma, cat. # D6421)
 9 L-Glutamine (Sigma, cat. # G7513)
 9 Penicillin/Streptomycin (Sigma, cat. # P4458)
 9 Hank’s Balanced Salt Solution (HBSS; with NaHCO3, without 
phenol red/Ca2+/Mg2+; Sigma, cat. # H6648)
 9 B-27 Supplement (Invitrogen, cat. # 17504044)
 9 N-2 Supplement (Invitrogen, cat. # 17502048)
 9 Poly-D lysine, poly-ornithine and laminin (Sigma, cat. # 
P1149, P4957, L2020)
 9 Nerve growth factor (NGF; R&D Systems, cat. # 256-GF-100)
 9 Broad_spectrum caspase inhibitor Boc_D_FMK (Calbiochem, 
cat. # 218745)
 9 Calcein-AM (Invitrogen, cat. # C1430)
 9 Transit 2020 Transfection Reagent (T2020) (Mirus, cat. # 
MIR6003)
 9 Phosphate-buffered saline (PBS) (without CaCl2 and MgCl2; 
Sigma, cat. # D5652)
 9 NeonTM Transfection System resuspension and electrolytic 
buffers (Invitrogen, cat. # MPK10025)
 9 Thiazolyl Blue Tetrazolium Bromide (MTT; Sigma, cat. # 
M5655)
 9 Methanol (Sigma, cat. # 322415)
 9 Paraformaldehyde (PFA; Sigma, cat. # P6148)
 9 Bovine serum albumin (BSA; Sigma, cat. # A2153)
 9 Mouse anti-tyrosine hydroxylase (TH; Millipore, cat. # 
MAB318)
 9 Mouse anti-β-actin (Sigma, cat. # A5441)
 9 Goat anti-mouse/rabbit Alexa Fluor 488/594-conjugated 
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secondary antibodies (Invitrogen, cat. # A11001, A11005, 
A11008, A11037)
 9 4’-6-Diamidino-2-phenylindole (DAPI; Sigma, cat. # D8417)
Recipes
 9 SH-SY5Y Media: DMEM-F12, containing 10% FBS, 100 nM 
L-Glutamine, 100 U/ml Penicillin/Streptomycin
 9 Differentiation Media: DMEM-F12 supplemented with 100 
nM L-Glutamine, 100 U/ml Penicillin/Streptomycin, 1% FBS 
and 2% B-27 Supplement
 9 SCG Media: DMEM-F12 supplemented with 100 nM L-Glu-
tamine, 100 U/ml Penicillin/Streptomycin, 1% N-2, 2% B-27 
and 10 ng/ml NGF (or 50 μM Boc_D_FMK)
PROCEDURE
The following is a step-wise procedure designed to identify and evaluate potential neurotrophic strategies in three 
cell culture models. The protocol uses the induction of neurite growth as the primary measure of neurotrophic action. 
The human SH-SY5Y neuroblastoma cell line is a model of human adrenergic and dopaminergic neurons. SH-SY5Y 
cells are first used to identify, screen and evaluate potential neurotrophic strategies, e.g., pharmacological agents (e.g., 
drugs/small molecules), signaling proteins (e.g., morphogens) and/or genetic (gene/mRNA) modifications. Effective 
neurotrophic strategies in SH-SY5Y cells are then evaluated in VM DA neurons and sympathetic neurons in vitro.
Evaluation of potential neurotrophic strategies in SH-SY5Y cells
1. Cell culture of human SH-SY5Y neuroblastoma cell line
1.1. Culture SH-SY5Y cells at a seeding density of 2 ×106 cells in a T25 flask in 10 ml of SH-SY5Y Media 
at 37°C in a humidified atmosphere containing 5% CO
2
.
1.2. When ~80% confluency is reached, remove media, wash cells in 1 ml of HBSS and then enzymatically 
dissociate in 0.2% trypsin by incubating at 370C for 5 min.
NOTE: At this density, ~80% confluency is reached after ~7 days in vitro (DIV).
1.3. Add 1 ml of SH-SY5Y Media to neutralize trypsin, and vigorously triturate cells 3–5 times using a 
plugged flame-polished Pasteur pipette (while avoiding air bubbles).
1.4. Prepare a 1:10 dilution of the cell suspension in media for cell counting with a haemocytometer. Count 
5 grids and calculate total number of cells/ml: Cells/ml = (Number of Cells Counted in 5 Fields)/5 × 
Dilution Factor × Haemocytometer Constant
1.5. Plate SH-SY5Y cells at a density of 50,000 cells/well (in 500 µl of media) in 24-well plate and incubate 
at 370C. Replace half of the media every 2–3 DIV (if no treatment).
2. Identification of viable working concentrations of potential neurotrophic agent in SH-SY5Y cells
2.1. From 1 DIV, treat SH-SY5Y cells with a range of doses/concentrations (e.g., 1, 10, 25, 50, 100, 200 
µM) of chosen pharmacological agent, or signaling protein, daily for 4 DIV. Treat control cells with 
equivalent volume of DMSO and/or HBSS.
NOTE: 4 DIV is optimal time point to analyze SH-SY5Y neurite growth [20].
2.2. To treat cells, prepare mixture of media and agent to give desired concentration in 500 µl of media/
well. Replace entire media with relevant treatment media.
TIP: Consult literature for effective doses of chosen potential neurotrophic agent in SH-SY5Y cells, or similar 
cells, to inform choice of concentrations range for testing.
2.3.  At 4 DIV, assess cell viability by performing an MTT Assay as follows:
2.4. Remove media from the wells of the 24 well plate, and incubate cells with 300 µl per well of 0.5 mg/
ml MTT in HBSS for 4 h at 37°C
NOTE: Phase-contrast images can be taken as observational measure of cell viability. A lactate dehydrogenase 
assay using the media can also be used to assess toxicity.
2.5. Carefully remove MTT solution from wells (do not disturb insoluble formazan).
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2.6. Add 100 µl of DMSO to each well to permeabilize formazan produced by the cells.
2.7. Pipette 75 µl of colored DMSO/formazan solution into a 96 well plate, and record the absorbance 
(αviability) of each sample using a plate reader at A600.
3.  Evaluation of neurite growth-induction ability of potential neurotrophic agent in SH-SY5Y cells
3.1. From 1 DIV, treat SH-SY5Y cells with viable dose(s) (from Step 1.2) daily for 4 DIV.
3.2. At 4 DIV, fix (4% PFA), block (5% BSA) and immunocytochemically stain SH-SY5Y cells for β-actin/
DAPI (as per ref. [20]) to allow visualization of cell cytoskeleton.
3.3. Alternatively, calcein-AM can be used for visualization of cell structure. To do this, add calcein-AM 
to culture media at a dilution of 1:1000 for 1 h before imaging.
NOTE: Image live cells immediately to avoid over-exposure of calcein-AM staining.
3.4. To measure neurite growth, image 20 microscopic fields per group, selected at random, at 200 × 
magnification (using a 20 × objective lens). Image both β-actin- and DAPI-stained cells in each field. 
Systematically image similar fields in every well to minimize bias. Measure all cells in each image 
using stereological procedures [21].
3.5. Open images in ImageJ and superimpose gridlines on the microscopic image. Using the ImageJ cell 
counter, manually count and record the number of times each neurite (β-actin- or calcein-AM-stained) 
intersects gridlines, and the number of cells (DAPI).
3.6. Calculate total neurite length using the formula; NL = α × T × (π/2) where α is the number of times 
the neurites intersect the grid lines, and T is the distance between the gridlines on the magnified image 
(taking into account the 200 × magnification factor).
NOTE: Measure T by superimposing gridlines on 200 × image of scaled 1 mm slide. T of 25 µm is recommended 
for SH-SY5Y cell neurite analysis.
3.7. Calculate neurite length per cell by diving total neurite length by number of cells within each image 
(to prevent differences in neurite length being due to cell number).
4.  Evaluation of neurite growth-induction ability of genetic modification in SH-SY5Y cells
4.1. To evaluate the potential neurotrophic role of a target gene/protein, and/or to verify results achieved 
in above pharmacological approaches, transfect SH-SY5Y cells with GFP (for visualization) and the 
plasmid(s) of interest (e.g., over-expression, siRNA).
4.2. For transfection, electroporate SH-SY5Y cells using the NeonTM Transfection System.
NOTE: Alternatively, lipo-transfection can be performed using the Transit 2020 Transfection Reagent, but yields 
lower transfection efficiency (see Troubleshooting).
4.3. Prepare cell suspension (as per Step 1), and then centrifuge required volume of cells to give 200,000 
cells/well at 1,100 rpm for 5 min. Wash cell pellet twice in PBS, and resuspend cells in required amount 
of resuspension buffer (12 µl per transfection).
4.4. Add 0.5 µg of GFP and 1 µg of desired plasmid to the resuspended cells, and aspirate 10 µl of the 
cells/plasmid DNA mixture into a gold Neon Tip using the Neon Pipette.
4.5. Place into cuvette, containing 3 ml of electrolytic buffer, in the Neon Pipette Station. Deliver electric 
pulse using optimized parameters: 1200 V, 20 ms width and 3 pulses.
TIP: Re-use expensive Neon Tips (≤ 10 times) and replace Neon buffers (as per ref. [22]).
4.6. Culture transfected cells (as per Step 1) for 4 DIV, and image 50 randomly selected transfected cells 
(GFP-expressing) per group for neurite growth analysis (as per Step 3).
5.  Evaluation of mechanisms of action of neurotrophic strategy in SH-SY5Y cells
5.1. To investigate, and/or verify, mechanism(s) of action of chosen neurotrophic strategy (pharmacological 
and/or genetic modifications) in SH-SY5Y cells, perform immunoblotting, immunocytochemistry and 
real-time PCR experiments (as per ref. [23]).
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5.2. For immunoblotting and real-time PCR experiments, plate 2 ×106 cells/well (in 2 ml of media) in a 
6-well plate to maximise yield of protein and RNA extraction.
5.3. Culture duration should be decided upon depending on protein/mRNA of interest, with hourly time-
course experiments recommended to examine signaling pathway activation, and longer time-points 
recommended to examine changes in expression.
5.4. Quantify protein levels from immunoblotting and immunocytochemistry experiments by densitometric 
analysis. For immunoblotting, express levels of protein of interest relative to levels of β-actin load-
ing control. For immunocytochemistry, calculate fluorescence intensity of each individual cell after 
subtracting background [23,24].
Evaluation of potential neurotrophic strategies in VM DA neurons
6. Dissection of E14 rat ventral midbrain (VM)
6.1. To dissect VM, place E14 rat embryos in HBSS in 90 mm Petri dish and keep on ice.
6.2. Using dissection microscope, make an incision at midbrain-hindbrain boundary, and at forebrain-mid-
brain boundary, using a dissecting scissors and a curved forceps.
TIP: Dissect in lid of petri dish with minimum amount of HBSS to cover lid of dish.
6.3. Cut dorsal midbrain along midline, and open/flatten-out midbrain to show VM in center. Cut along 
the lateral border of VM on either side, and then remove meninges.
TIP: Put one blade of scissors into the ventricle of midbrain neural tube to cut dorsal midline. Hold meninges down 
with scissors and carefully peel VM away with forceps.
6.4. Cut VM tissue cranially and caudally to ensure no fore-/hind-brain tissue is included.
6.5. Store dissected VMs in 15 ml centrifuge tube in HBSS on ice until completion.
7. Primary cell culture of E14 rat VM
7.1. Enzymatically dissociate dissected VM tissue by addition of 3 ml of 0.1% trypsin to centrifuge tube, 
and then incubating at 370C and 5% CO
2
 for 5 min.
7.2. Add 500 µl of FBS to neutralise the trypsin, and then triturate VM tissue using a pipette tip and a 
syringe and needle (× 3). Centrifuge VM cells at 1,100 rpm for 5 min.
7.3. Resuspend cell pellet in 1 ml of Differentiation Media. Prepare a 1:10 dilution of the cell suspension, 
using the Differentiation Media, for cell counting (as per Step 1).
7.4. Plate 50 µl of dissociated VM cells, at a density of 50,000 cells/well, in a poly-D-lysine-coated 24-
well plate for 2 h at 37°C, before adding 450 µl of media per well.
7.5. For coating, incubate wells with poly-D-lysine for 20 min, wash (H20 × 3) and dry.
7.6. Replace half of the Differentiation Media with fresh media every 2–3 DIV.
8. Evaluation of neurite growth-induction ability of potential neurotrophic agent in E14 rat VM DA neurons
8.1. From 1 DIV, treat E14 VM cells with neurotrophic agent (From Step 1) daily for 4 DIV.
8.2. At 4 DIV, fix (ice-cold methanol), block (5% BSA) and immunocytochemically stain E14 VM cells 
for TH/DAPI (as per ref. [23]) to allow visualization of VM DA neurons.
8.3. Measure total neurite length of 50 randomly selected TH-immunostained neurons per group at 100 
× magnification (using a 10 × objective lens) (as per Step 3). For primary neurons, count number of 
neurite branch points (point a neurite splits into two) also.
NOTE: T of 50 µm is recommended for cultured primary neurons.
9.  Evaluation of neurite growth-induction ability of genetic modification in E14 rat VM DA neurons
9.1. For transfection, electroporate E14 VM cells with neurotrophic effect-regulating genetic modification 
(from Step 1) using the NeonTM Transfection System (as per Step 4).
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9.2. Prepare cell suspension (as per Step 7), and then proceed as per Step 4 until electroporation of the 
VM cells using the optimized parameters: 1,100 V, 30 ms width and 2 pulses.
9.3. Culture transfected cells (as per Step 7) for 4 DIV, and image 50 randomly selected transfected VM 
neurons (GFP-expressing) per group for growth analysis (as per Step 8).
9.4. For neurite growth analysis of electroporated E14 VM DA neurons, immunocytochemically stain 
transfected VM cells for TH. Analyze 25 (low abundance) random GFP-expressing, TH-immunostained 
VM DA neurons per group.
NOTE: Anti-GFP antibody may be required if GFP signal is quenched upon fixation.
10. Evaluation of mechanisms of action of neurotrophic strategy in E14 VM cells
10.1. Investigate, and/or verify, mechanism(s) of action of chosen neurotrophic strategy in E14 VM cells 
as per Step 5. Plate 2×106 cells/well (in 2 ml of media) in a 6-well plate.
10.2. For immunocytochemistry experiments, immunocytochemically stain VM cells for both protein of 
interest and TH, to allow densitometric analysis in VM DA neurons.
Evaluation of potential neurotrophic strategies in sympathetic neurons
11. Dissection of P1 mouse superior cervical ganglia (SCG)
11.1. To dissect SCG, place P1 mouse or rat heads in HBSS in 90 mm Petri dish on ice.
11.2. Using dissection microscope, remove top of the skull along with the underlying brain.
11.3. Using the scissors, cut the head sagitally along the midline of the base of the skull.
11.4. Excise occipital bone to expose the SCG underneath, in each hemi-section of head.
11.5. Carefully remove SCG with a tweezer, before trimming it of non-SCG tissue.
11.6. Transfer dissected SCG, using an unplugged flame-polished Pasteur pipette, into a 15 ml conical 
centrifuge tube, and keep in HBSS on ice until dissections are complete.
NOTE: ‘Sticky’ SCG can become attached/stuck to the inside of plastic tips/tubes.
12. Primary cell culture of P1 mouse SCG
12.1. Chemically dissociate dissected SCG in 1 ml of 0.2% trypsin for 20 min at 370C.
12.2. Add 500 µl of FBS to neutralise trypsin, and aspirate trypsin/FBS solution carefully.
12.3. Resuspend SCG in required amount of SCG Media (80 µl per well). Using a narrow pipette tip, force-
fully pipette SCG against bottom of 15 ml tube to dissociate cells.
12.4. Plate 80 µl of SCG cells at a very low density (~200 neurons per dish) in poly-ornithine and lami-
nin-coated 4-well 35 mm tissue culture dishes for 2 h at 370C.
12.5. For coating, incubate wells with poly-ornithine for 2 h, wash (H20 × 3), and then incubate wells with 
laminin for 2 h at 370C. Remove laminin and air-dry wells.
12.6. Add 2 ml of SCG Media to dish, and culture for 24 h at 370C in 5% CO
2
.
13. Evaluation of neurite growth-induction ability of potential neurotrophic agent in P1 SCG sympathetic neurons
13.1. After 2 h of SCG cell plating, add treatment of neurotrophic agent (from Step 1) to the 2 ml of SCG 
media for 24 h. Each treatment requires a culture dish with 3 wells of SCG.
NOTE: NGF can be excluded from treatment media, and substituted with Boc_D_FMK. NGF should be included 
for 2 h of plating of SCG cells in wells of dish.
13.2. At 24 h, fix (ice-cold methanol), block (5% BSA) and immunocytochemically stain SCG cells for TH/
βIII-tubulin (as per ref. [23]) to allow visualization of SCG neurons.
NOTE: Alternatively, calcein-AM (1:1000) can be added to medium for visualization.
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13.3. Measure total neurite length of 50 randomly selected TH-immunostained neurons per group at 100 × 
magnification (as per Step 3). Count number of branch points (Fig. 1).
14. Evaluation of neurite growth-induction ability of genetic modification in P1 SCG sympathetic neurons
14.1. For transfection, electroporate SCG cells with neurotrophic effect-regulating genetic modification 
(from Step 1) using the NeonTM Transfection System (as per Step 4).
14.2. Prepare cell suspension (as per Step 12), and then proceed to electroporate as per Step 9.
14.3. Culture transfected cells (as per Step 12) for 24 h, and image 50 randomly selected transfected VM 
neurons (GFP-expressing) per group for growth analysis (as per Step 13).
15. Evaluation of mechanisms of action of neurotrophic strategy in P1 SCG sympathetic neurons. Investigate, 
and/or verify, mechanism(s) of action of chosen neurotrophic strategy in SCG cells as per Step 5. Due to 
low cell numbers, immunocytochemistry experiments are most suitable for examining protein(s) of interest.
Statistical analyses
16. Using GraphPad Prism software, perform unpaired student’s t-test or one-way ANOVA, with a post hoc 
Tukey’s or Bonferroni’s test as required, to determine significant differences (P < 0.05) between groups. 
17. Express results as means with standard errors, and repeat each experiment 3 times and in technical triplicate.
Figure 1. Neurite growth analysis of SCG sympathetic neurons. Representative photomicrographs of GFP-expressing P1 rat SCG neurons at 24 
h, with gridlines superimposed on ‘Neuron 1’. The grid intersections and branch points are indicated. The neurite length formula is described and an 
example of neurite growth analysis is depicted. Scale bar = 50 μm.
ANTICIPATED RESULTS
Evaluation of potential neurotrophic strategies in SH-
SY5Y cells
The authors have previously evaluated potential neurotrophic strate-
gies in SH-SY5Y cells using the procedures detailed above [20,24,25]. 
Identification of viable working concentrations of potential neurotrophic 
agents in SH-SY5Y cells can be achieved through MTT Assays. For 
example, to identify a viable working concentration of the potent in-
hibitor of histone acetyltransferases (HATs) p300 and PCAF Garcinol 
(Enzo Life Sciences), SH-SY5Y cells were treated with concentra-
tions ranging from 0.5–100 μM (Fig. 2A). These concentrations were 
selected based on IC50 values of Garcinol being 7 μM and 5 μM for 
p300 and PCAF, respectively. MTT Assays revealed that Garcinol had 
no effect on cell viability at concentrations 0.5 μM, 1 μM and 2.5 μM 
when compared to control (Fig. 2A). However, there was a significant 
reduction in cell viability at concentrations of 5 μM, 10 μM and 100 
μM of Garcinol treatment, compared to control (Fig. 2A). 0.5 μM and 
1 μM were then chosen as viable working concentrations for further 
Garcinol experimentation.
To evaluate potential neurotrophic strategies for PD-affected neu-
rons, the neurite growth-induction ability of pharmacological agents 
(e.g., drugs, compounds and small molecules), signaling proteins (e.g., 
morphogens) and/or genetic (e.g., gene and mRNA) modifications 
should first be performed in SH-SY5Y cells. For example, treatment 
of SH-SY5Y cells with 200 ng/ml of GDF5 (provided by Biopharm 
GmbH), a potent neurotrophic factor for VM DA neurons [13,14,15], 
or electroporation of SH-SY5Y cells with a constitutively-active, bone 
morphogenetic protein receptor Ib (caBMPRIb), results in significant 
increase in their neurite length at 4 DIV when compared to untreated 
cells transfected with a scramble control plasmid (Fig. 2B and ref. [20]).
Following identification of a potential neurotrophic strategy, it is 
important to evaluate and/or verify its mechanism(s) of action in SH-
SY5Y cells, before progressing with the neurotrophic strategy in VM DA 
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neurons and sympathetic neurons. Indeed, Smad signaling has previously 
been shown to mediate the neurotrophic effects of GDF5 using these 
methods in SH-SY5Y cells [20]. For example, Garcinol is a p300/PCAF 
HATs inhibitor, and should thus decrease histone acetylation in SH-SY5Y 
cells following treatment. To assess the ability of Garcinol to inhibit 
p300/PCAF HATs, the levels of acetylated-histone H3 were measured 
in SH-SY5Y cells by immunoblotting and immunocytochemistry, by 
using a rabbit anti-p-acetylated-histone H3 (ACH3; 1:200; Santa Cruz) 
primary antibody. Treatment of SH-SY5Y cells with 0.5 μM or 1 μM 
of Garcinol for 24 h significantly decreased the levels of ACH3 relative 
to control (Fig. 2C and 2D), following densitometric quantification of 
ACH3 immunocytochemically-stained SH-SY5Y cells (Fig. 2C), and 
of ACH3 protein levels relative to β-actin loading control (Fig. 2D). 
Therefore, Garcinol induces hypoacetylation of histone H3 in SH-SY5Y 
cells, likely through inhibition of p300/PCAF HATs.
Figure 2. Evaluation of potential neurotrophic strategies in SH-SY5Y cells. A. Standardised MTT assay of Garcinol-treated SH-SY5Y cells at 4 DIV. 
B. Graph showing the total neurite length/cell and representative photomicrographs of GFP-expressing GDF5-treated or caBMPRIb-transfected SH-
SY5Y cells, compared to an untreated scramble-transfected control at 4 DIV. C. Graph showing relative immunofluorescence intensity and representative 
photomicrographs of ACH3 in SH-SY5Y cells treated for 24 h with either control or Garcinol. As indicated (**P < 0.01, ***P < 0.001 vs. control; One-way 
ANOVA with post-hoc Tukey’s test). Number of repetitions (N) = 3. Scale bar = 100 μm. D. Western blotting showing ACH3 protein levels in SH-SY5Y 
cells treated for 24 h with control or Garcinol. β-actin was used as a loading control. Graph showing quantification of ACH3 protein levels in relation to 
β-actin levels, as indicated (*P < 0.05 vs. control; Unpaired student t-test; N = 3).
Figure 3. Evaluation of potential neurotrophic strategies in VM DA 
neurons. Graph showing the total neurite length/cell and representative 
photomicrographs of TH-immunostained E14 VM DA neurons treated with 
control or GDF5 at 4 DIV. As indicated (***P < 0.001 vs. control; Unpaired 
student t-test; N = 3). Scale bar = 100 μm.
Evaluation of potential neurotrophic strategies in dopa-
minergic neurons and sympathetic neurons
Following evaluation of a potential neurotrophic strategy in SH-SY5Y 
cells, the next step is to progress with the neurotrophic strategy in the 
PD-related VM DA neurons and sympathetic neurons. The authors have 
previously published such evaluations using the procedures outlined 
above [23,25,26]. For example, treatment of E14 VM cell cultures with 
GDF5, an effective neurotrophic strategy in SH-SY5Y cells, significantly 
increased the neurite length of E14 rat VM DA neurons at 4 DIV, when 
compared to untreated cells (Fig. 3 and ref. [23]). GDF5 treatment also 
induces significant neurite growth in P1 SCG neurons [26].
The mechanisms of neurotrophic action characterized in SH-SY5Y 
cells should also be examined in E14 VM DA neurons and P1 SCG sym-
pathetic neurons. We have previously shown that the neurite growth-pro-
moting mechanism of GDF5 is dependent on Smad signaling in SH-
SY5Y cells, E14 VM DA neurons and P1 SCG sympathetic neurons 
[20,23,26]. These findings were determined by genetic manipulations 
of the Smad signaling pathway following GDF5 treatment, and such 
experiments can be carried out using the protocol described herein. 
Furthermore, these studies demonstrate that neurotrophic signaling 
mechanisms can be conserved between these three cell culture models 
of the human neurons affected by PD. However, alternative cell-type 
specific mechanisms should also be considered when assessing potential 
neurotrophic action mechanisms in VM DA neurons and sympathetic 
neurons, respectively. For example, sympathetic neuronal growth is 
largely dependent on NGF signaling, while that of VM DA neurons is 
not [27,28,29,30].
TROUBLESHOOTING
Commonly and occasionally encountered problems in the procedure 
are listed in Table 1, along with the causes of such problems, as well 
as suggestions to prevent/correct these issues:
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Table 1: Troubleshooting of procedure.
Step Problem Cause Suggestion
1.2. Failure of trypsinisation Inhibitory FBS in residual media Ensure entire media is washed away with HBSS 
before trypsin
2.1. DMSO pools at centre of well & is 
toxic to the cells located at center
Dense DMSO sits at center of well when 
added directly to well
Add DMSO(-solubilized drugs) to media in tube, mix 
and add media/DMSO mixture to well
2.5. Loss of formazan Insoluble formazan crystals lost in MTT Do not agitate plate or disturb formazan when 
removing MTT
3.3./
13.2.
Hyper-exposed calcein-AM staining Incubation of live cells with calcein-AM 
> 2 h
Ensure calcein-AM stained cells are imaged in < 2 h
3.5. Underestimation of neurite length Gridlines with too large distance be-
tween lines
T of 25 µm is recommended for SH-SY5Y cell neurite 
analysis
4./9./14. Poor cell survival following transfec-
tion
Excessive time taken for electroporation 
protocol
Perform electroporation protocol in > 30 min
4./9./14. Poor transfection efficiency & survival Transfection protocol not optimized See ‘Transfection of Cultured Neural Cells Optimi-
zation’
5./10. Low protein yield Excessive lysate dilution Use 150 µl lysis buffer per well
5./10. Absence of activated signaling 
pathway(s)
Phosphorylation of proteins lost Use phosphatase inhibitors in lysis buffer
6.3. Meninges on VM tissue Inefficient removal of meninges from VM Peel VM tissue from meninges. Do not attempt to cut 
meninges
7.4. Unanalysable/misplaced neurons at 
edge of well
50 µl of plated cells spills to edges of 
well
Ensure 50 µl of plated cells remains at center of well
8.3./
13.3.
Underestimation of neurite length Gridlines with too large distance be-
tween lines
T of 50 µm is recommended for primary neuron 
growth analysis
9.4. GFP-positive cells lost Fixing can quench GFP Use anti-GFP antibody
11.5. Wrong ganglia dissected for cell 
culture
SCG & nodose ganglia similar & close 
together
SCG is distinctly larger than nodose ganglion
11.6. Loss of dissected SCG ‘Sticky’ SCG stuck in pipettes &/or tubes Use unplugged Pasteur pipette that can wash out 
with trypsin
3./4./8./
9./13./14.
Incorrect visualization of target 
neurons
Inappropriate labeling/
identification of neurons
See ‘Visualization of Cultured Neural Cells’
Transfection of cultured neural cells optimization
For optimization of lipo-transfection using Transit 2020 Transfection 
Reagent, 100,000 cells/well of SH-SY5Y and E14 rat VM cells were 
incubated in 24-well plates at 370C for 1 DIV. Lipo-transfection mix-
tures containing GFP plasmid at concentrations ranging from 0.25–2 
µg/ml and T2020 volumes (room temperature and gently vortexed) 
ranging from 0.5–4 µl were applied (drop-wise to different areas of 
their designated wells) to these cultured cells. It was identified that 0.5 
µg of GFP plasmid and 0.5 µl of T2020 gives the highest transfection 
efficiency (~20–30%) in SH-SY5Y cells (Fig. 4A), while 1.5 µg of 
GFP plasmid and 1 µl of T2020 gives the highest transfection efficiency 
(10–20%) in E14 VM cells (Fig. 4B). Similar transfection efficiencies 
but reductions in cell viability were observed with higher volumes (2–4 
µl) of T2020 (data not shown). For optimization of co-lipo-transfection, 
0.5 µg of the GFP plasmid and 1 µg of scramble vector were mixed 
with T2020 volumes ranging from 0.25–2 µl in SH-SY5Y cells. This 
identified that co-lipotransfection of SH-SY5Y cells with GFP and 
scramble plasmids and 2 µl of T2020 gives the highest co-transfection 
efficiency (~10–20%) in SH-SY5Y cells (Fig. 4C). However, there was a 
decrease in transfection efficiency and GFP expression in co-transfected 
SHSY5Y cells, when compared to GFP-transfected cells (Fig. 4A and 
4C). Co-lipo-transfection of E14 VM cells with GFP and scramble 
plasmids using T2020 volumes ranging from 0.25–2 µl resulted in no 
successfully co-lipo-transfected E14 VM cells (data not shown).
As a result of the poor co-transfection efficiencies using lipo-trans-
fection, optimization of the electroporation of SH-SY5Y and E14 VM 
cells was carried out. Cells were electroporated with GFP and scramble 
plasmids using a range of parameters: voltage (500–1500 V), width 
(10–30 ms) and pulses (1–3). Optimal parameters for SH-SY5Y cell 
electroporation were found to be 1200 V, 20 ms width and 3 pulses, which 
resulted in a co-transfection efficiency of ~70–80% (Fig. 4D), which 
was higher than that achieved by lipo-transfection (Fig. 4A and 4C). 
Co-transfection of E14 rat VM cells with GFP and scramble plasmids 
by electroporation was also performed successfully, with the highest 
efficiency (30–40%) achieved using the following parameters; 1100 
V, 30 ms width and 2 pulses (Fig. 4E). Due to cell type heterogeneity 
within primary VM cultures, the proportion of transfected VM neurons 
which are TH-positive is ~30%.
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Figure 4. Transfection of cultured neural cells optimization. A-E. Representative photomicrographs of SH-SY5Y (A, C, D) or E14 VM cells (B, E) 
lipo-transfected (A-C) or electroporated (D-E) with GFP (A-E) and/or scramble plasmids (C-E) at 1 DIV post-transfection. Scale bar = 100 μm.
Visualization of cultured neural cells
To visualize cultured cells for neurite growth analysis, immunocy-
tochemically stain SH-SY5Y cells, VM DA neurons and SCG sympa-
thetic neurons for β-actin (Fig. 5A), TH (Fig. 3) and TH/βIII-tubulin, 
respectively. Alternatively, SH-SY5Y cells and SCG sympathetic neurons 
can be visualized using calcein-AM (Fig. 5B). However, VM cultures 
contain a mixed population of neuronal subtypes, and calcein-AM is 
therefore unsuitable for selective visualization of VM DA neurons. When 
analyzing GFP-positive and/or calcein-AM-positive cells in primary 
cultures of VM (Fig. 5C) and SCG (Fig. 1 and Fig. 5B), ensure that 
only neurons, and not glia, are analyzed. Due to the sensitive nature 
of primary neuronal cultures, ensure that unhealthy cultures are not 
included in any analyses (Fig. 5D). Finally, to selectively analyze VM 
DA neurons in electroporated VM cell cultures, immunocytochemically 
stain for TH (and GFP if required), and then analyze neurite growth of 
GFP- and TH-positive VM neurons (Fig. 5E).
Figure 5. Visualization of cultured neural cells. A-E. Representative photomicrographs of SH-SY5Y (A), P1 SCG (B) or E14 VM (C-E) cells immuno-
cytochemically stained for β-actin (A) or TH (E), visualized with calcein-AM (B), and/or transfected with GFP (C-E) at 1 (B) or 4 (A, C-E) DIV. Neurons 
and Glia are indicated in B and C. Scale bar = 100 μm.
CONCLUSIONS
In order to develop novel NTF therapeutic strategies for PD, we 
need a systematic protocol for pre-clinical evaluation of potential 
neurotrophic strategies in the neuronal populations that are affected by 
PD. Before proceeding to experimentation in PD animal models, we 
first need to identify and evaluate potential neurotrophic agents in vitro. 
The present in vitro protocol allows a step-wise evaluation of potential 
neurotrophic strategies first in SH-SY5Y cells, and then in VM DA 
neurons and sympathetic neurons, populations which degenerate in PD 
[2-6,8-10]. As neurotrophic factors function to promote the survival 
and neurite growth of neurons during development and in adulthood, 
this protocol focuses on the induction of neurite growth as the primary 
measure of neurotrophic action. Indeed, neuro-protection/-restoration of 
PD-affected neurites is thought to be an appropriate target for effective 
therapeutic intervention in PD [19], and thus neurotrophic strategies 
which are effective at promoting neurite growth, identified using this 
protocol, have direct clinical potential in PD. In addition to this, the 
neurite growth methods described in this protocol can be applied to 
the study of neuronal growth in other scientific contexts, such as the 
study of regulators of neuronal development, innervation and plasticity. 
Similarly, the detailed description of primary culture of VM DA neurons 
and sympathetic neurons permits any desired study with these cells. 
For example, the VM DA neuronal cultures herein can also be used in 
the study of psychiatric disorders, in which a subset of these neurons 
are also implicated [31-33].
It has been previously suggested that NTF therapy clinical trials may 
have failed due to a disruption of the neurotrophic signaling mechanism 
in the PD brain. Therefore, the mechanisms of action of neurotrophic 
strategies need to be characterized and validated in pre-clinical stud-
ies. The protocol described in this paper permits the evaluation of the 
mechanisms of action of the neurtrophic strategy under investigation. 
Thereafter, such neurotrophic action mechanism(s) should be demon-
strated as functional in rodent models of PD (including α-synuclein rat 
model of PD) and the PD brain, before clinical trials with the potential 
neurotrophic strategy are considered in PD patients. Finally, the invasive 
nature and physiological limitations of intracerebral delivery of NTFs to 
the PD brain limits the potential of this therapy [15]. Novel neurotrophic 
strategies that could be applied peripherally, and which could protect the 
degenerating neurons in both the central and peripheral nervous system, 
would be the most suitable NTF therapy for PD. Evaluation of poten-
tial neurotrophic agents, such as blood-brain-barrier-permeable small 
molecules, which ideally could be modified to target the neuronal pop-
ulations affected by PD (e.g., selective uptake by TH-positive neurons) 
using our protocol would facilitate the development of such a therapy. 
In summary, this in vitro protocol provides a reliable, reproducible, 
robust and cost-effective means to identify, evaluate and characterize 
promising neurotrophic strategies in PD-related neurons, and serves 
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as a screening process to select novel therapeutic approaches for PD 
which are suitable for further testing in animal models and the clinic.
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